118 results on '"Biundo, R"'
Search Results
2. Correction to: Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion (Journal of Neurology, (2022), 269, 10, (5606-5614), 10.1007/s00415-022-11269-7)
- Author
-
Garri, F., Russo, F. P., Carrer, T., Weis, L., Pistonesi, F., Mainardi, M., Sandre, M., Savarino, E., Farinati, F., Del Sorbo, F., Soliveri, P., Calandrella, D., Biundo, R., Carecchio, M., Zecchinelli, A. L., Pezzoli, G., and Antonini, A.
- Published
- 2022
3. Cortical atrophy in patients with Parkinsonʼs disease and orthostatic hypotension: 1544
- Author
-
Pilleri, M., Weis, L., Marcon, V., Biundo, R., Facchini, S., and Antonini, A.
- Published
- 2014
4. Safety and efficacy of cognitive rehabilitation in PD with cognitive impairments: 919
- Author
-
Biundo, R., Weis, L., Facchini, S., Campo, M. C., Fiorenzato, E., Genitle, G., and Antonini, A.
- Published
- 2014
5. Performance at the Category-Exemplars language test (CATEX) in Parkinson's disease and Huntington's disease Italian population
- Author
-
Biundo, R, Gandolfi, T, Garon, M, Fiorenzato, E, Arcara, G, Jaquemont, C, Bisiacchi, P, Semenza, C, and Antonini, A
- Published
- 2020
6. Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson’s disease (PD_Manager): study protocol for a pilot randomised controlled trial
- Author
-
Antonini, A1, 2, Gentile, G2, Giglio, M2, Marcante, A1, Gage, H3, Touray, Mml4, Fotiadis, Di5, Gatsios, D5, Konitsiotis, S6, Timotijevic, L7, Egan, B7, Hodgkins, C7, Biundo, R2, Pellicano, C, Hatzakis, H, Correia Jesuino, Jorge, Antonini, A, Marcante, A, Biundo, R, Gentile, G, Manuela, G, Weis, L, Chiarot, M, Zanin, V, Seljak, Bk, Cestnik, B, Aleksovski, D, Miljkovic, D, Novak, F, Bohanec, M, Anzic, T, Podpecan, V, Valmarska, A, Papa, G, Blazica, B, Boshkoska, Bm, Vilzmann, R, Assogna, F, Spalletta, G, Pellicano, Gr, Palma, V, Scudellari, C, Soru, T, Napoletano, ANTONELLO MARIO, Fanciulli, F, Raffaelli, M, Banks, THOMAS ALLEN, Elliot, B, Hodgkins, C, Seiss, E, Gage, H, Timotijevic, L, Egan, B, Rusconi, P, Peacock, M, Gillies, S, Puttock, E, Touray, Mml, Gatsios, D, Rigas, G, Fotiadis, D, VON FALKENHAUSEN, VERA CHARLOTTE, Uceda, J, Mascato, Sv, de la Cal JR, Olmedo, Jjs, Martinez, F, Arrendondo, Mt, Cikajlo, I, and Peterlin-Potisk, K.
- Subjects
Male ,Health Knowledge, Attitudes, Practice ,Medicine (miscellaneous) ,Pilot Projects ,Disease ,law.invention ,Study Protocol ,0302 clinical medicine ,Acceptability ,Randomized controlled trial ,Utility ,Informed consent ,law ,Multicenter Studies as Topic ,Pharmacology (medical) ,030212 general & internal medicine ,mHealth ,Randomized Controlled Trials as Topic ,lcsh:R5-920 ,Delivery of Health Care, Integrated ,Parkinson Disease ,Telemedicine ,3. Good health ,Europe ,Treatment Outcome ,Caregivers ,Female ,lcsh:Medicine (General) ,medicine.medical_specialty ,Attitude of Health Personnel ,Clinical Decision-Making ,Control (management) ,acceptability ,cost consequence analysis ,Parkinson’s disease ,utility ,03 medical and health sciences ,Quality of life (healthcare) ,Physicians ,Intervention (counseling) ,medicine ,Humans ,Aged ,Patient Care Team ,Data collection ,business.industry ,Patient Acceptance of Health Care ,Physical therapy ,Cost consequence analysis ,business ,030217 neurology & neurosurgery - Abstract
Background Parkinson’s disease is a degenerative neurological condition causing multiple motor and non-motor symptoms that have a serious adverse effect on quality of life. Management is problematic due to the variable and fluctuating nature of symptoms, often hourly and daily. The PD_Manager mHealth platform aims to provide a continuous feed of data on symptoms to improve clinical understanding of the status of any individual patient and inform care planning. The objectives of this trial are to (1) assess patient (and family carer) perspectives of PD_Manager regarding comfort, acceptability and ease of use; (2) assess clinician views about the utility of the data generated by PD_Manager for clinical decision making and the acceptability of the system in clinical practice. Methods/design This trial is an unblinded, parallel, two-group, randomised controlled pilot study. A total of 200 persons with Parkinson’s disease (Hoehn and Yahr stage 3, experiencing motor fluctuations at least 2 h per day), with primary family carers, in three countries (110 Rome, 50 Venice, Italy; 20 each in Ioannina, Greece and Surrey, England) will be recruited. Following informed consent, baseline information will be gathered, including the following: age, gender, education, attitudes to technology (patient and carer); time since Parkinson’s diagnosis, symptom status and comorbidities (patient only). Randomisation will assign participants (1:1 in each country), to PD_Manager vs control, stratifying by age (1 ≤ 70 : 1 > 70) and gender (60% M: 40% F). The PD_Manager system captures continuous data on motor symptoms, sleep, activity, speech quality and emotional state using wearable devices (wristband, insoles) and a smartphone (with apps) for storing and transmitting the information. Control group participants will be asked to keep a symptom diary covering the same elements as PD_Manager records. After a minimum of two weeks, each participant will attend a consultation with a specialist doctor for review of the data gathered (by either means), and changes to management will be initiated as indicated. Patients, carers and clinicians will be asked for feedback on the acceptability and utility of the data collection methods. The PD_Manager intervention, compared to a symptom diary, will be evaluated in a cost-consequences framework. Discussion Information gathered will inform further development of the PD_Manager system and a larger effectiveness trial. Trial registration ISRCTN Registry, ISRCTN17396879. Registered on 15 March 2017. Electronic supplementary material The online version of this article (10.1186/s13063-018-2767-4) contains supplementary material, which is available to authorized users.
- Published
- 2018
7. Profile and progression of cognitive deficits in Progressive Supranuclear Palsy, Multiple System Atrophy and Parkinson's Disease
- Author
-
Fiorenzato, E, Antonini, A, Camparini, V, Weis, L, Semenza, C, and Biundo, R
- Published
- 2019
8. Non-invasive brain stimulation to treat cognitive symptoms of Parkinson's disease. Parkinsonism
- Author
-
Rektorova, I and Biundo, R.
- Published
- 2019
9. Subject drop in Italian Alzheimerʼs disease
- Author
-
Bencini, G., Biundo, R., Semenza, C., and Valian, V.
- Published
- 2005
- Full Text
- View/download PDF
10. Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD-Manager): Study protocol for a pilot randomised controlled trial 11 Medical and Health Sciences 1117 Public Health and Health Services
- Author
-
Antonini, A., Gentile, G., Giglio, M., Marcante, A., Gage, H., Touray, M. M. L., Fotiadis, D. I., Gatsios, D., Konitsiotis, S., Timotijevic, L., Egan, B., Hodgkins, C., Biundo, R., Pellicano, C., Hatzakis, H., Correia, J., Manuela, G., Weis, L., Chiarot, M., Zanin, V., Seljak, B. K., Cestnik, B., Aleksovski, D., Miljkovic, D., Novak, F., Bohanec, M., Anzic, T., Podpecan, V., Valmarska, A., Papa, G., Blazica, B., Boshkoska, B. M., Vilzmann, R., Assogna, F., Spalletta, G., Pellicano, G. R., Palma, V., Scudellari, C., Soru, T., Napoletano, M., Fanciulli, F., Raffaelli, M., Banks, A., Elliot, B., Seiss, E., Rusconi, P., Peacock, M., Gillies, S., Puttock, E., Rigas, G., Vera, C., Uceda, J., Mascato, S. V., De La Cal, J. R., Olmedo, J. J. S., Martinez, F., Arrendondo, M. T., Cikajlo, I., and Peterlin-Potisk, K.
- Subjects
Acceptability ,Cost consequence analysis ,mHealth ,Parkinson's disease ,Utility ,Aged ,Caregivers ,Clinical Decision-Making ,Delivery of Health Care, Integrated ,Europe ,Female ,Humans ,Male ,Multicenter Studies as Topic ,Parkinson Disease ,Patient Care Team ,Physicians ,Pilot Projects ,Randomized Controlled Trials as Topic ,Telemedicine ,Treatment Outcome ,Attitude of Health Personnel ,Health Knowledge, Attitudes, Practice ,Patient Acceptance of Health Care - Published
- 2018
11. Clinical variables associated with treatment changes in Parkinson’s disease: results from the longitudinal phase of the REASON study
- Author
-
Abbruzzese, Giovanni, Barone, Paolo, Ceravolo, Roberto, Fabbrini, Giovanni, Lessi, Patrizia, Ori, Alessandra, Simoni, Lucia, Tinazzi, Michele, Antonini, Angelo, Melone, MAB, Schettino, C, Capaldo, G, Iemolo, F, Sanzaro, E, Ceravolo, MG, Capecci, M, Andrenelli, E, Pontieri, FE, Pellicano, C, Benincasa, D, Fabbrini, G, Pietracupa, S, Latorre, A, Tedeschi, G, Tessitore, A, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, Volonté, MA, Spagnolo, F, Scaglioni, A, Abrignani, G, Abbruzzese, G, Avanzino, L, Tamburini, T, Antonini, A, Facchini, S, Biundo, R, Altavista, MC, Roberti, C, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, Del Sette, M, Carabelli, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, Stampanoni Bassi, M, Tinazzi, M, Ottaviani, S, Ajena, D, Trianni, G, Caggiula, M, Valenti, G, My, F, Grioli, S, La Farina, I, Zambito Marsala, S, Marchini, C, Gioulis, M, Asteggiano, G, L’Episcopo, MR, Saracco, E, Barone, P, Picillo, M, Moccia, M, Onofrj, M, Thomas, A, Denaro, A, Marini, C, De Santis, F, Spagnoli, V, L’Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, Marchet, A., Abbruzzese, Giovanni, Barone, Paolo, Ceravolo, Roberto, Fabbrini, Giovanni, Lessi, Patrizia, Ori, Alessandra, Simoni, Lucia, Tinazzi, Michele, Antonini, Angelo, Melone, Mab, Schettino, C, Capaldo, G, Iemolo, F, Sanzaro, E, Ceravolo, Mg, Capecci, M, Andrenelli, E, Pontieri, Fe, Pellicano, C, Benincasa, D, Fabbrini, G, Pietracupa, S, Latorre, A, Tedeschi, G, Tessitore, A, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, Volonté, Ma, Spagnolo, F, Scaglioni, A, Abrignani, G, Abbruzzese, G, Avanzino, L, Tamburini, T, Antonini, A, Facchini, S, Biundo, R, Altavista, Mc, Roberti, C, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, Del Sette, M, Carabelli, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, Stampanoni Bassi, M, Tinazzi, M, Ottaviani, S, Ajena, D, Trianni, G, Caggiula, M, Valenti, G, My, F, Grioli, S, La Farina, I, Zambito Marsala, S, Marchini, C, Gioulis, M, Asteggiano, G, L’Episcopo, Mr, Saracco, E, Barone, P, Picillo, M, Moccia, M, Onofrj, M, Thomas, A, Denaro, A, Marini, C, De Santis, F, Spagnoli, V, L’Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, and Marchet, A.
- Subjects
Male ,medicine.medical_specialty ,Clinical variables ,Neurology ,Parkinson's disease ,Motor symptoms ,Non-motor symptoms ,Parkinson’s disease ,Treatment persistence ,Aged ,Female ,Humans ,Longitudinal Studies ,Middle Aged ,Parkinson Disease ,Physician's Role ,Severity of Illness Index ,Treatment Outcome ,Neurology (clinical) ,Psychiatry and Mental Health ,2708 ,Longitudinal Studie ,Dermatology ,Disease ,Internal medicine ,motor symptoms,non-motor symptoms ,Parkinson’s disease,treatment persistence ,Severity of illness ,Medicine ,Neuroradiology ,business.industry ,musculoskeletal, neural, and ocular physiology ,General Medicine ,medicine.disease ,nervous system diseases ,cardiovascular system ,Physical therapy ,Neurosurgery ,business ,Human - Abstract
To assess over a period of 9 months in a sample of Italian Parkinson’s disease (PD) patients reasons leading the neurologist to modify dopaminergic treatment and patients’ causes of dissatisfaction with ongoing therapy. To evaluate the influence of disease severity on therapy persistence. A disease severity balanced sample of PD patients with stable anti-parkinsonian drugs (APD) treatment was enrolled and evaluated every 3 months. Patients requiring APD treatment modifications were discontinued from the study. The probability to modify APD treatment is greater for higher motor (UPDRS scores) and non-motor symptoms (NMSS score) severity. Both from neurologist’s and patient’s perspective, motor symptoms were the main determinants underlying APD treatment modifications. Non-motor symptoms were cause of dissatisfaction with ongoing APD treatment for 52 % of the patients, while only 36 % of the neurologists considered these as valid reasons for therapy change. REASON is the first study in PD patients that prospectively examined reasons driving APD treatment changes. Results show that the disease severity significantly increases the probability of APD treatment change. Patients attribute greater relevance than neurologists to non-motor symptoms as reason requiring treatment changes. This confirms that patient and neurologist perceptions only partially overlap.
- Published
- 2015
12. Adherence to anti-Parkinson drug therapy in the 'REASON' sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the 'Morisky Medical Adherence Scale-8 items'
- Author
-
Fabbrini, G, Abbruzzese, G, Barone, P, Antonini, A, Tinazzi, M, Castegnaro, G, Rizzoli, S, Morisky, De, Lessi, P, Abbruzzese G, Cr, Ceravolo, R, Melone, M, Schettino, C, Califano, F, Ceravolo, M, Capecci, M, Andrenelli, E, Iemolo, F, Spadaro, D, Carnemolla, A, Pontieri, F, Pellicano, C, Benincasa, D, Pietracupa, S, Latorre, A, Tedeschi, G, Tessitore, A, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, Volonté, M, Spagnolo, F, Scaglioni, A, Abrignani, G, Avanzino, L, Tamburini, T, Facchini, S, Biundo, R, Altavista, M, Roberti, C, Asteggiano, G, L'Episcopo, M, Saracco, E, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, Del Sette, M, Carabelli, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, Stampanoni Bassi, M, Ottaviani, S, Ajena, D, Trianni, G, My, F, Caggiula, M, Valenti, G, Grioli, S, La Farina, I, Zambito Marsala, S, Marchini, C, Gioulis, M, Picillo, M, Moccia, M, Denaro, A, Sebastianelli, L, Onofrj, M, Thomas, A, Marini, C, De Santis, F, Spagnoli, V, L'Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, Marchet, A, Ori, A, Pirondi, S, Roncari, B, Sala, S, Sgarbi, S, Simoni, L, Trevisan, F, Zanoli, L, Fabbrini, G, Abbruzzese, G, Antonini, A, Barone, P, Ceravolo, R, Tinazzi, M, Melone, Mariarosa Anna Beatrice, Schettino, C, Califano, F, Ceravolo, Mg, Capecci, M, Andrenelli, E, Iemolo, F, Spadaro, D, Carnemolla, A, Pontieri, Fe, Pellicano, C, Benincasa, D, Pietracupa, S, Latorre, A, Tedeschi, Gioacchino, Tessitore, Alessandro, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, Volonté, Ma, Spagnolo, F, Scaglioni, A, Abrignani, G, Avanzino, L, Tamburini, T, Facchini, S, Biundo, R, Altavista, Mc, Roberti, C, Asteggiano, G, L'Episcopo, Mr, Saracco, E, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, Nullm, nullDel Sette, Carabelli, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, Nullm, nullStampanoni Bassi, Ottaviani, S, Ajena, D, Trianni, G, My, F, Caggiula, M, Valenti, G, Grioli, S, Nulli, nullLa Farina, Nulls, nullZambito Marsala, Marchini, C, Gioulis, M, Picillo, M, Moccia, M, Denaro, A, Sebastianelli, L, Onofrj, M, Thomas, A, Marini, C, Nullf, nullDe Santi, Spagnoli, V, L'Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, Marchet, A, Lessi, P, Castegnaro, G, Ori, A, Pirondi, S, Rizzoli, S, Roncari, B, Sala, S, Sgarbi, S, Simoni, L, Trevisan, F, Zanoli, L., Fabbrini, G., Abbruzzese, G., Barone, P., Antonini, A., Tinazzi, M., Castegnaro, G., Rizzoli, S., Morisky, D. E., Lessi, P., Ceravolo, R., Melone, M. A., Schettino, C., Califano, F., Ceravolo, M. G., Capecci, M., Andrenelli, E., Iemolo, F., Spadaro, D., Carnemolla, A., Pontieri, F. E., Pellicano, C., Benincasa, D., Pietracupa, S., Latorre, A., Tedeschi, G., Tessitore, A., Giordano, A., Bonuccelli, U., Frosini, D., Vanelli, F., Comi, G., Volonte, M. A., Spagnolo, F., Scaglioni, A., Abrignani, G., Avanzino, L., Tamburini, T., Facchini, S., Biundo, R., Altavista, M. C., Roberti, C., Asteggiano, G., L'Episcopo, M. R., Saracco, E., Avarello, T., Bono, G., Riboldazzi, G., Leva, S., Del Sette, M., Carabelli, E., Traverso, E., Michelucci, R., Nassetti, S., Pasini, E., Padovani, A., Cottini, E., Bigni, B., Ruggieri, S., Modugno, N., Fischetti, M., Stefani, A., Pierantozzi, M., Stampanoni Bassi, M., Ottaviani, S., Ajena, D., Trianni, G., My, F., Caggiula, M., Valenti, G., Grioli, S., La Farina, I., Zambito Marsala, S., Marchini, C., Gioulis, M., Picillo, M., Moccia, M., Denaro, A., Sebastianelli, L., Onofrj, M., Thomas, A., Marini, C., De Santis, F., Spagnoli, V., L'Erario, R., Passadore, P., Belgrado, E., Mucchiut, M., Priori, A., Cogiamanian, F., Marchet, A., Ori, A., Pirondi, S., Roncari, B., Sala, S., Sgarbi, S., Simoni, L., Trevisan, F., Morisky, De, Comi, Giancarlo, and REASON study, Group
- Subjects
Predictive validity ,Male ,Translation ,Parkinson's disease ,Adherence ,Comprehension ,Validation ,Aged ,Antiparkinson Agents ,Female ,Humans ,Parkinson Disease ,Translations ,Medication Adherence ,Surveys and Questionnaires ,Neurology (clinical) ,Psychiatry and Mental Health ,2708 ,MEDLINE ,Dermatology ,Disease ,Linguistic validation ,Pharmacotherapy ,Quality of life ,Medicine ,business.industry ,General Medicine ,Parkinson’s disease ,medicine.disease ,Psychiatry and Mental health ,Antiparkinson Agent ,Settore MED/26 - Neurologia ,business ,Human ,Clinical psychology - Abstract
Information about patients' adherence to therapy represents a primary issue in Parkinson's disease (PD) management. To perform the linguistic validation of the Italian version of the self-rated 8-Item Morisky Medical Adherence Scale (MMAS-8) and to describe in a sample of Italian patients affected by PD the adherence to anti-Parkinson drug therapy and the association between adherence and some socio-demographic and clinical features. MMAS-8 was translated into Italian language by two independent Italian mother-tongue translators. The consensus version was then back-translated by an English mother-tongue translator. This translation process was followed by a consensus meeting between the authors of translation and investigators and then by two comprehension tests. The translated version of the MMAS-8 scale was then administered at the baseline visit of the "REASON" study (Italian Study on the Therapy Management in Parkinson's disease: Motor, Non-Motor, Adherence and Quality Of Life Factors) in a large sample of PD patients. The final version of the MMAS-8 was easily understood. Mean ± SD MMAS-8 score was 6.1 ± 1.2. There were no differences in adherence to therapy in relationship to disease severity, gender, educational level or decision to change therapy. The Italian version of MMAS-8, the key tool of the REASON study to assess the adherence to therapy, has shown to be understandable to patients with PD. Patients enrolled in the REASON study showed medium therapy adherence.
- Published
- 2013
13. Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study
- Author
-
Tinazzi, M, Abbruzzese, G, Antonini, A, Ceravolo, R, Fabbrini, G, Lessi, P, Barone, P, REASON Study Group:Abruzzese, G, Lido, V, Melone, M, Schettino, C, Califano, F, Ceravolo, M, Capecci, M, Andrenelli, E, Iemolo, F, Spadaro, D, Carnemolla, A, Pontieri, F, Pellicano, C, Benincasa, D, Pietracupa, S, Latorre, A, Tedeschi, G, Tessitore, A, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, Volonté, M, Spagnolo, F, Scaglioni, A, Abrignani, G, Avanzino, L, Tamburini, T, Facchini, S, Biundo, R, Altavista, M, Roberti, C, Asteggiano, G, L'Episcopo, M, Saracco, E, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, Del, S, Carabelli, M, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, Bassi, M, Ottaviani, S, Ajena, D, Trianni, G, My, F, Caggiula, M, Valenti, G, Grioli, S, La Farina, I, Zambito Marsala, S, Marchini, C, Gioulis, M, Picillo, M, Moccia, M, Denaro, A, Sebastianelli, L, Onofrj, M, Thomas, A, Marini, C, De Santis, F, Spagnoli, V, L'Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, Marchet, A, Tinazzi, M, Abbruzzese, G, Antonini, A, Ceravolo, R, Fabbrini, G, Lessi, P, Barone, P, Lido, V, Melone, M, Schettino, C, Califano, F, Ceravolo, Mg, Capecci, M, Andrenelli, E, Iemolo, F, Spadaro, D, Carnemolla, A, Pontieri, F, Pellicano, C, Benincasa, D, Pietracupa, S, Latorre, A, Tedeschi, G, Tessitore, A, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, Volonté, M, Spagnolo, F, Scaglioni, A, Abrignani, G, Avanzino, L, Tamburini, T, Facchini, S, Biundo, R, Altavista, M, Roberti, C, Asteggiano, G, L'Episcopo, M, Saracco, E, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, Del, Sette, M, Carabelli, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, Bassi, M, Ottaviani, S, Ajena, D, Trianni, G, My, F, Caggiula, M, Valenti, G, Grioli, S, La, Farina, I, Zambito, Marsala, S, Marchini, C, Gioulis, M, Picillo, M, Moccia, M, Denaro, A, Sebastianelli, L, Onofrj, M, Thomas, A, Marini, C, De, Santi, F, Spagnoli, V, L'Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, Marchet, A., Tinazzi, M., Abbruzzese, G., Antonini, A., Ceravolo, R., Fabbrini, G., Lessi, P., Barone, P., Melone, M. A. B., Schettino, C., Califano, F., Ceravolo, M. G., Capecci, M., Andrenelli, E., Iemolo, F., Spadaro, D., Carnemolla, A., Pontieri, F. E., Pellicano, C., Benincasa, D., Pietracupa, S., Latorre, A., Tedeschi, G., Tessitore, A., Giordano, A., Bonuccelli, U., Frosini, D., Vanelli, F., Comi, G., Volonte, M. A., Spagnolo, F., Scaglioni, A., Abrignani, G., Avanzino, L., Tamburini, T., Facchini, S., Biundo, R., Altavista, M. C., Roberti, C., Asteggiano, G., L'Episcopo, M. R., Saracco, E., Avarello, T., Bono, G., Riboldazzi, G., Leva, S., Del Sette, M., Carabelli, E., Traverso, E., Michelucci, R., Nassetti, S., Pasini, E., Padovani, A., Cottini, E., Bigni, B., Ruggieri, S., Modugno, N., Fischetti, M., Stefani, A., Pierantozzi, M., Stampanoni Bassi, M., Ottaviani, S., Ajena, D., Trianni, G., My, F., Caggiula, M., Valenti, G., Grioli, S., La Farina, I., Zambito Marsala, S., Marchini, C., Gioulis, M., Picillo, M., Moccia, M., Denaro, A., Sebastianelli, L., Onofrj, M., Thomas, A., Marini, C., De Santis, F., Spagnoli, V., L'Erario, R., Passadore, P., Belgrado, E., Mucchiut, M., Priori, A., Cogiamanian, F., Lessi, and Comi, Giancarlo
- Subjects
Male ,Pediatrics ,Parkinson's disease ,anti-Parkinson drugs ,motor symptoms ,non-motor symptoms ,Practice Patterns ,Socioeconomic Factor ,Motor symptoms ,Severity of Illness Index ,Antiparkinson Agents ,Cohort Studies ,Motor symptom ,Practice Patterns, Physicians' ,Stage (cooking) ,Anti-Parkinson drug ,Anti-Parkinson drugs ,Non-motor symptoms ,Aged ,Female ,Humans ,Middle Aged ,Parkinson Disease ,Patient Satisfaction ,Socioeconomic Factors ,Geriatrics and Gerontology ,Neurology (clinical) ,Neurology ,musculoskeletal, neural, and ocular physiology ,Antiparkinson Agent ,cardiovascular system ,Settore MED/26 - Neurologia ,Treatment modification ,Human ,medicine.medical_specialty ,Non-motor symptom ,Disease severity ,medicine ,In patient ,Physicians' ,business.industry ,Advanced stage ,medicine.disease ,nervous system diseases ,Physical therapy ,Treatment decision making ,Cohort Studie ,business - Abstract
OBJECTIVES: To assess the association between clinical and socio-demographic features and anti-Parkinson drug (APD) treatment modifications in patients with PD and to describe neurologist and patient opinions regarding the need for changes in APD therapy. METHODS: Subjects with PD with stable APD treatment over ≥3 months prior to baseline were enrolled and evaluated for socio-demographic data, disability, disease severity and neurologist and patient views on the need to modify APD treatment. RESULTS: 775 Patients were included, 51% with Hoehn and Yahr (HY) stage 1-2 (early PD) and 49% with HY stage 2.5-4 (advanced PD). Neurologists modified APD treatment in 255 patients, 97 (25%) early PD and 158 (41%; p < 0.0001) advanced PD. APD modification was strongly associated with a low educational level and UPDRS part IV score. The most common reasons behind the APD therapy changes among neurologists were presence/worsening of motor or non-motor symptoms (88% and 37% of subjects respectively). Out of 216 patients, 92% and 51% were willing to undergo APD changes to therapy because of the presence/worsening of motor or non-motor symptoms. CONCLUSIONS: Neurologist decision to change APD therapy and patients reasons for dissatisfaction with it can be prevalently attributed to the presence/worsening of motor symptoms and motor fluctuations in the advanced stages. Non-motor symptoms were considered more often by patients. The patient educational level played a key role in treatment decision.
- Published
- 2013
14. Erratum: Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients with Mild Cognitive Impairment Receiving Cognitive Training
- Author
-
Bisiacchi, P., Antonini, Angelo, Biundo, R., Weis, Fiorenzato, L., Gentile, E., Giglio, G., Schifano, M., Campo, R., Marcon, M. C., and Martinez Martin, V.
- Published
- 2016
15. Brain structural abnormalities in multiple system atrophy patients with cognitive impairment
- Author
-
Fiorenzato, E., Biundo, R., Luca Weis, Seppi, K., Onofrj, M., Cortelli, P., Kaufmann, H., Poewe, W., Krismer, F., Wenning, G., and Antonini, A.
- Published
- 2016
16. Erratum: Double-blind Randomized Trial of tDCS Versus Sham in Parkinson Patients with Mild Cognitive Impairment Receiving Cognitive Training (Brain Stimulation (2015) 8 (1223-1225) DOI: 10.1016/j.brs.2015.07.043)
- Author
-
Biundo, R., Weis, Luca, Fiorenzato, L., Gentile, E., Giglio, G., Schifano, M., Campo, R., Marcon, M. C., Martinez Martin, V., Bisiacchi, P., and Antonini, Angelo
- Published
- 2016
17. Anatomical profile of cognitive impairment in MSA
- Author
-
Fiorenzato, E., Biundo, R., Weis, L., Seppi, K., Onofrj, M., Cortelli, P., Kaufmann, H., Krismer, F., Wenning, G., Antonini, A., and on behalf of the MODIMSA neuropsychology and imaging working groups
- Subjects
medicine.medical_specialty ,Neurology ,business.industry ,medicine ,Neurology (clinical) ,Geriatrics and Gerontology ,Audiology ,Cognitive impairment ,business - Published
- 2016
18. Validation of the Italian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
- Author
-
Antonini, A, Abbruzzese, G, Ferini Strambi, L, Tilley, B, Huang, J, Stebbins, Gt, Goetz, Cg, Barone, P, MDS UPDRS Italian Validation Study Group, Bandettini di Poggio, M, Fabbrini, G, Di Stasio, F, Tinazzi, M, Bovi, T, Ramat, S, Meoni, S, Pezzoli, G, Canesi, M, Martinelli, P, Maria Scaglione CL, Rossi, A, Tambasco, N, Santangelo, G, Picillo, M, Morgante, Letterio, Morgante, Francesca, Quatrale, R, Sensi, M, Pilleri, M, Biundo, R, Nordera, G, Caria, A, Pacchetti, C, Zangaglia, R, Lopiano, L, Zibetti, M, Zappia, M, Nicoletti, A, Quattrone, A, Salsone, M, Cossu, G, Murgia, D, Albanese, A, Del Sorbo, F., Antonini, A, Abbruzzese, G, Ferini Strambi, L, Tilley, B, Huang, J, Stebbins, Gt, Goetz, Cg, Barone, P, MDS UPDRS Italian Validation Study, Group, Bandettini di Poggio, M, Fabbrini, G, Di Stasio, F, Tinazzi, M, Bovi, T, Ramat, S, Meoni, S, Pezzoli, G, Canesi, M, Martinelli, P, Maria Scaglione, Cl, Rossi, A, Tambasco, N, Santangelo, Gabriella, Picillo, M, Morgante, L, Morgante, F, Quatrale, R, Sensi, M, Pilleri, M, Biundo, R, Nordera, G, Caria, A, Pacchetti, C, Zangaglia, R, Lopiano, L, Zibetti, M, Zappia, M, Nicoletti, A, Quattrone, A, Salsone, M, Cossu, G, Murgia, D, Albanese, A, and Del Sorbo, F.
- Subjects
Male ,Unified Parkinson's Disease Rating Scale ,Mds updrs ,Parkinson's disease ,Unified Parkinson’s Disease Rating Scale ,Unified Parkinson's disease rating scale ,Dermatology ,Neuropsychological Tests ,Factor structure ,Severity of Illness Index ,MDS-UPDRS ,rating scale ,rating scales ,Disability Evaluation ,Rating scale ,Medical ,Humans ,Translations ,Societies, Medical ,Neurologic Examination ,Protocol (science) ,Movement Disorders ,Movement (music) ,Reproducibility of Results ,Parkinson Disease ,General Medicine ,Statistical ,Linguistics ,Focus (linguistics) ,Settore MED/26 - NEUROLOGIA ,Psychiatry and Mental health ,Italy ,Index (publishing) ,Female ,Neurology (clinical) ,Societies ,Factor Analysis, Statistical ,Psychology ,Factor Analysis ,Social psychology - Abstract
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has been available in English since 2008. As part of this process, the MDS-UPDRS organizing team developed guidelines for development of official non- English translations. We present here the formal process for completing officially approved non-English versions of the MDS-UPDRS and specifically focus on the first of these versions in Italian. The MDS-UPDRS was translated into Italian and tested in 377 native-Italian speaking PD patients. Confirmatory and exploratory factor analyses determined whether the factor structure for the English- language MDS-UPDRS could be confirmed in data col- lected using the Italian translation. To be designated an 'Official MDS translation,' the Comparative Fit Index (CFI) had to be C0.90 relative to the English-language version. For all four parts of the Italian MDS-UPDRS, the CFI, in comparison with the English-language data, was C0.94. Exploratory factor analyses revealed some differ- ences between the two datasets, however these differences were considered to be within an acceptable range. The Italian version of the MDS-UPDRS reaches the criterion to be designated as an Official Translation and is now avail- able for use. This protocol will serve as outline for further validation of this in multiple languages.
- Published
- 2013
19. Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease
- Author
-
Biundo, R., Weis, Facchini, L., Formento Dojot, S., Vallelunga, P., Pilleri, A., Weintraub, M., and Antonini, Angelo
- Published
- 2015
20. Safety and efficacy of cognitive rehabilitation in PD with cognitive impairments
- Author
-
Biundo, R., Luca Weis, Facchini, S., Campo, M. C., Fiorenzato, E., Genitle, G., and Antonini, A.
- Published
- 2014
21. Subject drop in Italian Alzheimer’s disease
- Author
-
BENCINI G, BIUNDO R, SEMENZA, CARLO, Bencini, G, Biundo, R, and Semenza, Carlo
- Published
- 2005
22. Validation of the Italian version of Parkinson's disease-cognitive rating scale (PD-CRS)
- Author
-
Santangelo, G., Barone, P., Abbruzzese, G., Ferini Strambi, L., Antonini, A, Bandettini, M., Fabbrini, G., Di Stasio, F., Tinazzi, M., Bovi, T., Ramat, S., Meoni, S., Pezzoli, G., Siri, C., Canesi, M., Martinelli, P., Scaglione, C. L., Rossi, A., Tambasco, N., Picillo, M., Morgante, Letterio, Morgante, Francesca, Quatrale, R., Sensi, M. C., Pilleri, M., Biundo, R., Nordera, G., Caria, A., Pacchetti, C., Zangaglia, R., Lopiano, L., Zibetti, M., Morgante, L., Morgante, F., Zappia, M., Nicoletti, A., Quattrone, A., Salsone, M., Cossu, G., Murgia, D., Albanese, A., Del Sorbo, F., Santangelo, Gabriella, Barone, Paolo, Abbruzzese, Giovanni, Ferini-strambi, Luigi, and Antonini, Angelo
- Subjects
Male ,medicine.medical_specialty ,Parkinson's disease ,Neurology ,Dermatology ,Audiology ,Neuropsychological Tests ,Cognition Disorder ,Cognitive dysfunction ,Rating scale ,medicine ,Dementia ,Humans ,Cognitive dysfunctions ,Mild cognitive impairment ,Parkinson's Disease Cognitive Rating Scale (PD-CRS) ,Aged ,Cognition Disorders ,Female ,Italy ,Middle Aged ,Parkinson Disease ,Neurology (clinical) ,Psychiatry and Mental Health ,2708 ,Psychiatry ,Working memory ,Cognition ,General Medicine ,medicine.disease ,Confidence interval ,Psychiatry and Mental health ,Ceiling effect ,Neuropsychological Test ,Psychology ,Human - Abstract
Cognitive impairment (CI) is a frequent feature associated with both early and advanced stages of Parkinson's disease (PD). An evaluation of cognitive functions is relevant to identify those parkinsonians at risk of developing dementia. In the present study, the Italian version of Parkinson's Disease-Cognitive Rating Scale (PD-CRS) assessing fronto-subcortical and cortical cognitive functions in PD was validated in 387 parkinsonians and was used to test the empirical validity of the item 1.1 (cognitive impairment) of the Italian version of MDS-UPDRS as screening tool for CI in PD. PD-CRS was free from floor and ceiling effect. The mean PD-CRS score was 76.1 (mean cortical score, 24.5 ± 4.6; mean subcortical score, 51.5 ± 17.5). The internal consistency was satisfactory (α = 0.89); corrected item-total correlation was 0.570 (naming) to 0.696 (working memory). The correlation between PD-CRS and part I-IV of MDS-UPDRS was weak. The low agreement between classification of PD sample into patients with mild cognitive impairment (PD-MCI), dementia (PD-D) and normal cognition (PD-NC) according to scores of item 1.1 and classification according to cutoff scores of PD-CRS for PD-MCI, PD-D and PD-NC indicated a poor empirical validity of item 1.1 of MDS-UPDRS as cognitive screening tool for CI in PD (Π= 0.114; weighted Π= 0.17; SE of Π= 0.038; 95 % confidence interval from 0.040 to 0.1895). The Italian version of PD-CRS is an easy, consistent and valid tool for assessment of the cognitive cortical and subcortical impairments in PD. © 2013 Springer-Verlag.
- Published
- 2013
23. Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study
- Author
-
Michele, Tinazzi, Giovanni, Abbruzzese, Antonini, Angelo, Roberto, Ceravolo, Giovanni, Fabbrini, Patrizia, Lessi, Barone, Paolo, Giovanni, Abruzzese, Venezia, Lido, M A, B Melone, Schettino, C, Califano, F, G Ceravolo, M, Capecci, M, Andrenelli, E, Iemolo, F, Spadaro, D, Carnemolla, A, E Pontieri, F, Pellicano, C, Benincasa, D, Fabbrini, G, Pietracupa, S, Latorre, A, Tedeschi, G, Tessitore, A, Giordano, A, Bonuccelli, U, Frosini, D, Vanelli, F, Comi, G, A Volonté, M, Spagnolo, F, Scaglioni, A, Abrignani, G, Abbruzzese, G, Avanzino, L, Tamburini, T, Antonini, A, Facchini, S, Biundo, R, C Altavista, M, Roberti, C, Asteggiano, G, R L'Episcopo, M, Saracco, E, Avarello, T, Bono, G, Riboldazzi, G, Leva, S, M Del Sette, Carabelli, E, Traverso, E, Michelucci, R, Nassetti, S, Pasini, E, Padovani, A, Cottini, E, Bigni, B, Ruggieri, S, Modugno, N, Fischetti, M, Stefani, A, Pierantozzi, M, M Stampanoni Bassi, Tinazzi, M, Ottaviani, S, Ajena, D, Trianni, G, F, My, Caggiula, M, Valenti, G, Grioli, S, I La Farina, S Zambito Marsala, Marchini, C, Gioulis, M, Barone, P, Picillo, M, Moccia, M, Denaro, A, Sebastianelli, L, Onofrj, M, Thomas, A, Marini, C, F De Santis, Spagnoli, V, L'Erario, R, Passadore, P, Belgrado, E, Mucchiut, M, Priori, A, Cogiamanian, F, and Marchet, A
- Published
- 2013
24. Language Specific Effects in Alzheimer’s disease: Subject Omission in Italian and English
- Author
-
Bencini, G, Pozzan, L, Mcgeown, W, Valian, V, Venneri, A, Semenza, Carlo, and Biundo, R
- Published
- 2011
25. The neuroanatomical substrate of lexical-semantic decline in MCI APOE ε4 carriers and noncarriers
- Author
-
Venneri, A, Mcgeown, Wj, Biundo, R, Mion, M, Nichelli, P, and Shanks, Mf.
- Published
- 2011
26. Subject drop in Italian Alzheimer's disease
- Author
-
Bencini, G, Biundo, R, Semenza, C, and Valian, V
- Published
- 2005
27. Validation of the Italian version of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale
- Author
-
Antonini, A., Abbruzzese, G., Ferini-Strambi, L., Tilley, B., Huang, J., Stebbins, G. T., Goetz, C. G., Barone, P., Bandettini Di Poggio, M., Fabbrini, G., Di Stasio, F., Tinazzi, M., Bovi, T., Ramat, S., Meoni, S., Pezzoli, G., Canesi, M., Martinelli, P., Maria Scaglione, C. L., Rossi, A., Tambasco, N., Santangelo, G., Picillo, M., Morgante, L., Morgante, F., Quatrale, R., Sensi, M., Pilleri, M., Biundo, R., Nordera, G., Caria, A., Pacchetti, C., Zangaglia, R., Lopiano, L., Zibetti, M., Zappia, M., Nicoletti, A., Quattrone, A., Salsone, M., Cossu, G., Murgia, D., Albanese, Alberto, Del Sorbo, F., Albanese A. (ORCID:0000-0002-5864-0006), Antonini, A., Abbruzzese, G., Ferini-Strambi, L., Tilley, B., Huang, J., Stebbins, G. T., Goetz, C. G., Barone, P., Bandettini Di Poggio, M., Fabbrini, G., Di Stasio, F., Tinazzi, M., Bovi, T., Ramat, S., Meoni, S., Pezzoli, G., Canesi, M., Martinelli, P., Maria Scaglione, C. L., Rossi, A., Tambasco, N., Santangelo, G., Picillo, M., Morgante, L., Morgante, F., Quatrale, R., Sensi, M., Pilleri, M., Biundo, R., Nordera, G., Caria, A., Pacchetti, C., Zangaglia, R., Lopiano, L., Zibetti, M., Zappia, M., Nicoletti, A., Quattrone, A., Salsone, M., Cossu, G., Murgia, D., Albanese, Alberto, Del Sorbo, F., and Albanese A. (ORCID:0000-0002-5864-0006)
- Abstract
The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has been available in English since 2008. As part of this process, the MDS-UPDRS organizing team developed guidelines for development of official non-English translations. We present here the formal process for completing officially approved non-English versions of the MDS-UPDRS and specifically focus on the first of these versions in Italian. The MDS-UPDRS was translated into Italian and tested in 377 native-Italian speaking PD patients. Confirmatory and exploratory factor analyses determined whether the factor structure for the English-language MDS-UPDRS could be confirmed in data collected using the Italian translation. To be designated an 'Official MDS translation,' the Comparative Fit Index (CFI) had to be ≥0.90 relative to the English-language version. For all four parts of the Italian MDS-UPDRS, the CFI, in comparison with the English-language data, was ≥0.94. Exploratory factor analyses revealed some differences between the two datasets, however these differences were considered to be within an acceptable range. The Italian version of the MDS-UPDRS reaches the criterion to be designated as an Official Translation and is now available for use. This protocol will serve as outline for further validation of this in multiple languages. © 2012 Springer-Verlag.
- Published
- 2013
28. 1.304 THE ANATOMICAL CORRELATES OF FREEZING OF GAIT IN PARKINSON'S DISEASE
- Author
-
Pilleri, M., primary, Biundo, R., additional, Bernardi, L., additional, and Antonini, A., additional
- Published
- 2012
- Full Text
- View/download PDF
29. 2.030 PATTERNS OF CORTICAL AND SUB-CORTICAL THINNING IN PARKINSON'S DISEASE
- Author
-
Biundo, R., primary, Calabrese, M., additional, Ricchieri, G., additional, Facchini, S., additional, Pilleri, M., additional, Gallo, P., additional, and Antonini, A., additional
- Published
- 2012
- Full Text
- View/download PDF
30. The neuroanatomical substrate of lexical-semantic decline in MCI APOE ε4 carriers and noncarriers.
- Author
-
Venneri A, McGeown WJ, Biundo R, Mion M, Nichelli P, Shanks MF, Venneri, Annalena, McGeown, William J, Biundo, Roberta, Mion, Marco, Nichelli, Paolo, and Shanks, Michael F
- Abstract
Lexical-semantic competency in mild cognitive impairment (MCI) ε4 carriers was used as an endophenotype, and gray matter volume in MCI ε4 carriers/noncarriers and in noncarrier controls was compared. Residual gray matter volumes were correlated with age of acquisition values for words from a category fluency task, an index of semantic competency. MCI patients had significantly impoverished lexical-semantic output compared with controls, more marked in MCI ε4 carriers. Smaller volumes in the left hippocampus, bilateral regions of the uncus, and posterior cingulate cortex were associated with a tendency to retrieve earlier acquired words in the category fluency task in MCI ε4 carriers, whereas poor semantic performance in MCI noncarriers was associated with smaller volumes in the left uncus, bilateral regions of the parahippocampal gyrus, and hippocampus, and also in a large number of neocortical regions. There was a significant semantic competency by genotype interaction in the left perirhinal cortex, in a number of left frontal and temporal areas and in the right inferior parietal lobule and precuneus. MCI ε4 carriers, when compared with noncarriers, had lower gray matter volume values confined to the right precuneus and the cerebellum bilaterally, but the converse comparison showed that MCI noncarriers had lower values in extensive frontal, temporal, and parietal regions of the neocortex. Similar brain volumetric variations linked to genotype were found in minimal-to-mild AD. The results suggest a relatively specific impact of apolipoprotein E (APOE) ε4 burden and underline the value of linguistic assessment in preclinical diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
31. MMSE and MoCA feasibility in Parkinson's disease and dementia with Lewy bodies: A multicenter 1-year follow-up study
- Author
-
Biundo, R., Luca Weis, Bostantjopoulou, S., Stefanova, E., Falup-Pecurariu, C., Kramberger, M. G., Geurtsen, G., Antonini, A., Weintraub, D., and Aarsland, D.
32. The interplay between asymmetric dopaminergic degeneration, brain structural changes and cognition in de-novo PD: The PPMI dataset
- Author
-
Fiorenzato, E., Antonini, A., Weis, W., Bisiacchi, P., Semenza, C., Antonino Vallesi, and Biundo, R.
- Subjects
Cognitive dysfunction ,Cognitive dysfunction, Dopaminergic neurons, Parkinsonism, Parkinson Disease ,Parkinson Disease ,Parkinsonism ,Dopaminergic neurons
33. Amyloid deposition affects cognitive manifestations in Parkinson's disease: The PPMI dataset
- Author
-
Fiorenzato, E., Biundo, R., Cecchin, D., Frigo, A. C., Luca Weis, Kim, J., Strafella, A., and Antonini, A.
34. Cognitive profiling in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a 15-month longitudinal study
- Author
-
Fiorenzato, E., Luca Weis, Antonini, A., and Biundo, R.
35. Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial.
- Author
-
Antonini, A., Gentile, G., Giglio, M., Marcante, A., Gage, H., Touray, M.M.L., Fotiadis, D.I., Gatsios, D., Konitsiotis, S., Timotijevic, L., Egan, B., Hodgkins, C., Biundo, R., Pellicano, C., Seiss, Ellen, PD_Manager consortium, Antonini, A., Gentile, G., Giglio, M., Marcante, A., Gage, H., Touray, M.M.L., Fotiadis, D.I., Gatsios, D., Konitsiotis, S., Timotijevic, L., Egan, B., Hodgkins, C., Biundo, R., Pellicano, C., Seiss, Ellen, and PD_Manager consortium
- Abstract
BACKGROUND: Parkinson's disease is a degenerative neurological condition causing multiple motor and non-motor symptoms that have a serious adverse effect on quality of life. Management is problematic due to the variable and fluctuating nature of symptoms, often hourly and daily. The PD_Manager mHealth platform aims to provide a continuous feed of data on symptoms to improve clinical understanding of the status of any individual patient and inform care planning. The objectives of this trial are to (1) assess patient (and family carer) perspectives of PD_Manager regarding comfort, acceptability and ease of use; (2) assess clinician views about the utility of the data generated by PD_Manager for clinical decision making and the acceptability of the system in clinical practice. METHODS/DESIGN: This trial is an unblinded, parallel, two-group, randomised controlled pilot study. A total of 200 persons with Parkinson's disease (Hoehn and Yahr stage 3, experiencing motor fluctuations at least 2 h per day), with primary family carers, in three countries (110 Rome, 50 Venice, Italy; 20 each in Ioannina, Greece and Surrey, England) will be recruited. Following informed consent, baseline information will be gathered, including the following: age, gender, education, attitudes to technology (patient and carer); time since Parkinson's diagnosis, symptom status and comorbidities (patient only). Randomisation will assign participants (1:1 in each country), to PD_Manager vs control, stratifying by age (1 ≤ 70 : 1 > 70) and gender (60% M: 40% F). The PD_Manager system captures continuous data on motor symptoms, sleep, activity, speech quality and emotional state using wearable devices (wristband, insoles) and a smartphone (with apps) for storing and transmitting the information. Control group participants will be asked to keep a symptom diary covering the same elements as PD_Manager records. After a minimum of two weeks, each participant will attend a consultation with a specialist doc
36. Development and Validation of Automated <scp>Magnetic Resonance</scp> Parkinsonism Index 2.0 to Distinguish <scp>Progressive Supranuclear Palsy‐Parkinsonism</scp> From <scp>Parkinson's Disease</scp>
- Author
-
Andrea Quattrone, Maria G. Bianco, Angelo Antonini, David E. Vaillancourt, Klaus Seppi, Roberto Ceravolo, Antonio P. Strafella, Gioacchino Tedeschi, Alessandro Tessitore, Roberto Cilia, Maurizio Morelli, Salvatore Nigro, Basilio Vescio, Pier Paolo Arcuri, Rosa De Micco, Mario Cirillo, Luca Weis, Eleonora Fiorenzato, Roberta Biundo, Roxana G. Burciu, Florian Krismer, Nikolaus R. McFarland, Christoph Mueller, Elke R. Gizewski, Mirco Cosottini, Eleonora Del Prete, Sonia Mazzucchi, Aldo Quattrone, Quattrone, A., Bianco, M. G., Antonini, A., Vaillancourt, D. E., Seppi, K., Ceravolo, R., Strafella, A. P., Tedeschi, G., Tessitore, A., Cilia, R., Morelli, M., Nigro, S., Vescio, B., Arcuri, P. P., De Micco, R., Cirillo, M., Weis, L., Fiorenzato, E., Biundo, R., Burciu, R. G., Krismer, F., Mcfarland, N. R., Mueller, C., Gizewski, E. R., Cosottini, M., Del Prete, E., and Mazzucchi, S.
- Subjects
Magnetic Resonance Spectroscopy ,Parkinson's disease ,Magnetic Resonance Parkinsonism Index 2.0 ,Parkinson Disease ,automated MRI biomarker ,progressive supranuclear palsy-parkinsonism ,Magnetic Resonance Imaging ,eye diseases ,Diagnosis, Differential ,Parkinsonian Disorders ,Neurology ,Humans ,Paralysis ,Supranuclear Palsy, Progressive ,Neurology (clinical) - Abstract
Background: Differentiating progressive supranuclear palsy-parkinsonism (PSP-P) from Parkinson's disease (PD) is clinically challenging. Objective: This study aimed to develop an automated Magnetic Resonance Parkinsonism Index 2.0 (MRPI 2.0) algorithm to distinguish PSP-P from PD and to validate its diagnostic performance in two large independent cohorts. Methods: We enrolled 676 participants: a training cohort (n=346; 43 PSP-P, 194 PD, and 109 control subjects) from our center and an independent testing cohort (n=330; 62 PSP-P, 171 PD, and 97 control subjects) from an international research group. We developed a new in-house algorithm for MRPI 2.0 calculation and assessed its performance in distinguishing PSP-P from PD and control subjects in both cohorts using receiver operating characteristic curves. Results: The automated MRPI 2.0 showed excellent performance in differentiating patients with PSP-P from patients with PD and control subjects both in the training cohort (area under the receiver operating characteristic curve [AUC]=0.93 [95% confidence interval, 0.89–0.98] and AUC=0.97 [0.93–1.00], respectively) and in the international testing cohort (PSP-P versus PD, AUC=0.92 [0.87–0.97]; PSP-P versus controls, AUC=0.94 [0.90–0.98]), suggesting the generalizability of the results. The automated MRPI 2.0 also accurately distinguished between PSP-P and PD in the early stage of the diseases (AUC=0.91 [0.84–0.97]). A strong correlation (r=0.91, P < 0.001) was found between automated and manual MRPI 2.0 values. Conclusions: Our study provides an automated, validated, and generalizable magnetic resonance biomarker to distinguish PSP-P from PD. The use of the automated MRPI 2.0 algorithm rather than manual measurements could be important to standardize measures in patients with PSP-P across centers, with a positive impact on multicenter studies and clinical trials involving patients from different geographic regions. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Published
- 2022
37. I conductores dei saltus africani: conflitti sociali e economici nella gestione della proprietà imperiale
- Author
-
R. BIUNDO, M. Maiuro, G.D. Merola, M. De Nardis, G. Soricelli, and Biundo, R.
- Subjects
salutus africani, gestione terre imperiali, iscrizioni africane - Abstract
Il presente studio si propone di analizzare alcune iscrizioni africane di epoca imperiale romana (II-III sec. d.C.), dalle quali emergono una serie di conflitti sociali e economici relativi alla gestione dei fondi di proprietà imperiale in Africa. Viene esaminato in particolare il ruolo dei conductores, che prendono in appalto la gestione delle terre in questione e che, in diverse occasioni, essendo diversi gli interessi economici in gioco, entrano in conflitto con i coloni che quelle terre coltivano.
- Published
- 2019
38. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders.
- Author
-
Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, and Antonini A
- Published
- 2012
39. Les femmes dans l’économie romaine: femmes évergètes et eau
- Author
-
R. Biundo and Biundo, R.
- Subjects
Storia delle donne, evergetismo, mondo romano, gestione dell'acqua, economia romana - Abstract
Les femmes occupent, au sein de la société romaine, une place très importante soit du point de vu sociale, que économique. Elles n’ont aucun accès au pouvoir politique, ne possèdent ni des droits actifs (droit de vote ou de recouvrir des magistratures), ni passifs (être élues), cependant peuvent participer à la vie civile, obtenir des importantes charges religieuses, mais surtout ont le droit d’hériter et de posséder des patrimoines. Certaines femmes, surtout dans une période où l’émancipation féminine est en croissance (à partir du Ier siècle ap. J.-C.), décident de gérer leur patrimoine (personnellement ou à travers des représentants), d’investir et de se lancer dans le monde de l’entreprenariat. En cherchant le prestige ailleurs que dans la politique active, les femmes aisées, au pair des hommes riches, peuvent venir en aide de leurs cités à travers des actes d’évergétisme, en leur offrent les finances pour la construction ou la restauration d’édifices publiques nécessaires à la communauté. Nous connaissons certains cas de femmes romaines qui financent la construction ou la restauration d’aqueducs. Encore une fois, depuis l’élément mythologique par exemple des nymphes protectrices des eaux, la femme est connexe à l’eau et notamment à la « protection » de l’eau. Le but de cette intervention est celui d’examiner le rôle de la femme dans l’économie romaine, son rapport avec les ressources en eau et leur gestion, à partir de l’interprétation des sources littéraires et épigraphiques, mais aussi à travers la lecture des représentations sociales qui émergent de nos sources historiques.
40. Genetic mutations in Parkinson's disease: screening of a selected population from North-Eastern Italy.
- Author
-
Bonato G, Antonini A, Pistonesi F, Campagnolo M, Guerra A, Biundo R, Pilleri M, Bertolin C, Salviati L, and Carecchio M
- Abstract
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder with a multifactorial pathogenesis. Several genetic variants increase the risk of PD and about 5-10% of cases are monogenic. This study aims to define the genetic bases and clinical features of PD in a cohort of patients from Northeastern Italy, a peculiar geographical area previously not included in genetic screenings., Methods: Using an NGS multigenic panel, 218 PD patients were tested based on age at onset, family history and development of atypical features., Results: A total of 133 genetic variants were found in 103 patients. Monogenic PD was diagnosed in 43 patients (20% of the cohort); 28 (12.8%) carried mutations in GBA1, 10 in LRRK2 (4.6%) and 5 in PRKN (2.3%). In 17% of patients the genetic defect remained of uncertain interpretation. The selection criterion "age of onset < 55 years" was a significant predictor of a positive genetic test (OR 3.8, p 0.0037). GBA1 patients showed more severe symptoms and a higher burden of motor and non-motor complications compared to negative patients (dyskinesias OR 3, sleep disturbances OR 2.8, cognitive deficits OR 3.6; p < 0.05), with greater autonomic dysfunction (COMPASS-31 score 34.1 vs 20.2, p 0.03)., Conclusions: Applying simple clinical criteria for genetic testing allows to increase the probability to identify patients with monogenic PD and better allocate resources. This process is critical to widen the understanding of disease mechanisms and to increase the individuation of patients potentially benefitting from future disease-modifying therapies., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
41. Facial emotion recognition in individuals with mild cognitive impairment: An exploratory study.
- Author
-
Burgio F, Menardi A, Benavides-Varela S, Danesin L, Giustiniani A, Van den Stock J, De Mitri R, Biundo R, Meneghello F, Antonini A, Vallesi A, de Gelder B, and Semenza C
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Parkinson Disease physiopathology, Parkinson Disease diagnostic imaging, Recognition, Psychology physiology, Neuropsychological Tests, Brain diagnostic imaging, Brain physiopathology, Cognitive Dysfunction physiopathology, Cognitive Dysfunction diagnostic imaging, Facial Recognition physiology, Facial Expression, Emotions physiology, Magnetic Resonance Imaging
- Abstract
Understanding facial emotions is fundamental to interact in social environments and modify behavior accordingly. Neurodegenerative processes can progressively transform affective responses and affect social competence. This exploratory study examined the neurocognitive correlates of face recognition, in individuals with two mild cognitive impairment (MCI) etiologies (prodromal to dementia - MCI, or consequent to Parkinson's disease - PD-MCI). Performance on the identification and memorization of neutral and emotional facial expressions was assessed in 31 individuals with MCI, 26 with PD-MCI, and 30 healthy controls (HC). Individuals with MCI exhibited selective impairment in recognizing faces expressing fear, along with difficulties in remembering both neutral and emotional faces. Conversely, individuals with PD-MCI showed no differences compared with the HC in either emotion recognition or memory. In MCI, no significant association emerged between the memory for facial expressions and cognitive difficulties. In PD-MCI, regression analyses showed significant associations with higher-level cognitive functions in the emotional memory task, suggesting the presence of compensatory mechanisms. In a subset of participants, voxel-based morphometry revealed that the performance on emotional tasks correlated with regional changes in gray matter volume. The performance in the matching of negative expressions was predicted by volumetric changes in brain areas engaged in face and emotional processing, in particular increased volume in thalamic nuclei and atrophy in the right parietal cortex. Future studies should leverage on neuroimaging data to determine whether differences in emotional recognition are mediated by pathology-specific atrophic patterns., (© 2024. The Psychonomic Society, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
42. Validation of the Italian version of the Parkinson's Disease- Cognitive Functional Rating Scale.
- Author
-
Garon M, Weis L, Siquier A, Fiorenzato E, Pistonesi F, Cianci V, Canesi M, Pesce F, Reali E, Pozzi B, Isaias IU, Siri C, Santangelo G, Cuoco S, Barone P, Kulisevsky J, Antonini A, and Biundo R
- Subjects
- Male, Female, Humans, Reproducibility of Results, Neuropsychological Tests, Cognition, Italy, Parkinson Disease complications, Parkinson Disease diagnosis, Cognitive Dysfunction diagnosis, Cognitive Dysfunction etiology, Dementia
- Abstract
A key distinguishing factor between mild cognitive impairment (MCI) and dementia in Parkinson's disease (PD) lies in the notable decrease in functioning due to cognitive impairment. The Parkinson's Disease-Cognitive Functional Rating Scale (PD-CRFS) was developed to assess functional limitations caused by cognitive impairment, while reducing the influence of motor impairment. The aim of this multicenter study was to (i) validate the Italian version of the PD-CFRS in PD, (ii) determine optimal cut-off scores for detecting MCI and dementia in PD, (iii) compare its performances with the most established functional assessment tool (IADL). Six hundred and sixty nine PD participants were recruited from 4 Italian Movement Disorders centers (Venice, Milan, Gravedona, and Salerno). They underwent Level-II cognitive evaluation, which resulted in 282 PD-NC, 310 PD-MCI, and 77 PDD. The PD-CFRS's psychometric and clinimetric properties, applicability, and responsiveness were analyzed. The PD-CFRS showed high acceptability. Floor and ceiling effects were acceptable. It also displayed strong internal consistency (Cronbach's α = 0.738), and test-retest reliability (ICC = .854). The PD-CFRS demonstrated higher coefficient of variation to detect dysfunction in PD-MCI patients in comparison to the IADL scale (PD-CFRS 96% vs IADL 22.5%). Convergent validity with the IADL was r = - 0.638 and - 0.527 in males and females, respectively. PD-CFRS total score negatively correlated with global cognition (MoCA corrected score r = - 0.61; p < 0.001). A cut-off score > 6.5 identified PDD with a sensitivity of 90% and specificity of 88% (AUC = .959). A cut-off value of > 1 detected PD-MCI with a sensitivity of 68% and specificity of 69% (AUC = .695). The Italian version of the PD-CFRS demonstrated to be an easy, valid and reliable tool that properly captures functional impairment due to cognitive decline in PD. It also proved to be particularly effective in the advanced stages of PD, and would be a useful support for the diagnosis of PD-MCI and PDD., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
43. Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease.
- Author
-
Fiorenzato E, Moaveninejad S, Weis L, Biundo R, Antonini A, and Porcaro C
- Subjects
- Humans, Brain pathology, Brain Mapping, Magnetic Resonance Imaging methods, Neuropsychological Tests, Parkinson Disease complications, Parkinson Disease diagnostic imaging, Parkinson Disease pathology, Cognitive Dysfunction diagnostic imaging, Cognitive Dysfunction etiology, Cognitive Dysfunction pathology, Dementia
- Abstract
Background: Higuchi's fractal dimension (FD) captures brain dynamics complexity and may be a promising method to analyze resting-state functional magnetic resonance imaging (fMRI) data and detect the neuronal interaction complexity underlying Parkinson's disease (PD) cognitive decline., Objectives: The aim was to compare FD with a more established index of spontaneous neural activity, the fractional amplitude of low-frequency fluctuations (fALFF), and identify through machine learning (ML) models which method could best distinguish across PD-cognitive states, ranging from normal cognition (PD-NC), mild cognitive impairment (PD-MCI) to dementia (PDD). Finally, the aim was to explore correlations between fALFF and FD with clinical and cognitive PD features., Methods: Among 118 PD patients age-, sex-, and education matched with 35 healthy controls, 52 were classified with PD-NC, 46 with PD-MCI, and 20 with PDD based on an extensive cognitive and clinical evaluation. fALFF and FD metrics were computed on rs-fMRI data and used to train ML models., Results: FD outperformed fALFF metrics in differentiating between PD-cognitive states, reaching an overall accuracy of 78% (vs. 62%). PD showed increased neuronal dynamics complexity within the sensorimotor network, central executive network (CEN), and default mode network (DMN), paralleled by a reduction in spontaneous neuronal activity within the CEN and DMN, whose increased complexity was strongly linked to the presence of dementia. Further, we found that some DMN critical hubs correlated with worse cognitive performance and disease severity., Conclusions: Our study indicates that PD-cognitive decline is characterized by an altered spontaneous neuronal activity and increased temporal complexity, involving the CEN and DMN, possibly reflecting an increased segregation of these networks. Therefore, we propose FD as a prognostic biomarker of PD-cognitive decline. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., (© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.)
- Published
- 2024
- Full Text
- View/download PDF
44. Deep brain stimulation of globus pallidus internus and subthalamic nucleus in Parkinson's disease: a multicenter, retrospective study of efficacy and safety.
- Author
-
Mainardi M, Ciprietti D, Pilleri M, Bonato G, Weis L, Cianci V, Biundo R, Ferreri F, Piacentino M, Landi A, Guerra A, and Antonini A
- Subjects
- Humans, Globus Pallidus, Retrospective Studies, Treatment Outcome, Subthalamic Nucleus, Parkinson Disease therapy, Deep Brain Stimulation adverse effects, Deep Brain Stimulation methods, Suicide
- Abstract
Background: Deep brain stimulation (DBS) is an established therapeutic option in advanced Parkinson's disease (PD). Literature data and recent guidelines remain inconclusive about the best choice as a target between the subthalamic nucleus (STN) and the globus pallidus internus (GPi)., Materials and Methods: We retrospectively reviewed the clinical efficacy outcomes of 48 DBS-implanted patients (33 STN-DBS and 15 GPi-DBS) at a short- (<1 year from the surgery) and long-term (2-5 years) follow-up. Also, clinical safety outcomes, including postoperative surgical complications and severe side effects, were collected., Results: We found no difference between STN-DBS and GPi-DBS in improving motor symptoms at short-term evaluation. However, STN-DBS achieved a more prominent reduction in oral therapy (L-DOPA equivalent daily dose, P = .02). By contrast, GPi-DBS was superior in ameliorating motor fluctuations and dyskinesia (MDS-UPDRS IV, P < .001) as well as motor experiences of daily living (MDS-UPDRS II, P = .03). The greater efficacy of GPi-DBS on motor fluctuations and experiences of daily living was also present at the long-term follow-up. We observed five serious adverse events, including two suicides, all among STN-DBS patients., Conclusion: Both STN-DBS and GPi-DBS are effective in improving motor symptoms severity and complications, but GPi-DBS has a greater impact on motor fluctuations and motor experiences of daily living. These results suggest that the two targets should be considered equivalent in motor efficacy, with GPi-DBS as a valuable option in patients with prominent motor complications. The occurrence of suicides in STN-treated patients claims further attention in target selection., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
45. Delivering Multidisciplinary Rehabilitation Care in Parkinson's Disease: An International Consensus Statement.
- Author
-
Goldman JG, Volpe D, Ellis TD, Hirsch MA, Johnson J, Wood J, Aragon A, Biundo R, Di Rocco A, Kasman GS, Iansek R, Miyasaki J, McConvey VM, Munneke M, Pinto S, St Clair KA, Toledo S, York MK, Todaro R, Yarab N, and Wallock K
- Subjects
- Humans, Quality of Life, Speech Therapy, Parkinson Disease, Occupational Therapy, Disabled Persons
- Abstract
Background: Parkinson's disease (PD) is a complex neurodegenerative disorder impacting everyday function and quality of life. Rehabilitation plays a crucial role in improving symptoms, function, and quality of life and reducing disability, particularly given the lack of disease-modifying agents and limitations of medications and surgical therapies. However, rehabilitative care is under-recognized and under-utilized in PD and often only utilized in later disease stages, despite research and guidelines demonstrating its positive effects. Currently, there is a lack of consensus regarding fundamental topics related to rehabilitative services in PD., Objective: The goal of the international Parkinson's Foundation Rehabilitation Medicine Task Force was to develop a consensus statement regarding the incorporation of rehabilitation in PD care., Methods: The Task Force, comprised of international multidisciplinary experts in PD and rehabilitation and people directly affected by PD, met virtually to discuss topics such as rehabilitative services, existing therapy guidelines and rehabilitation literature in PD, and gaps and needs. A systematic, interactive, and iterative process was used to develop consensus-based statements on core components of PD rehabilitation and discipline-specific interventions., Results: The expert-based consensus statement outlines key tenets of rehabilitative care including its multidisciplinary approach and discipline-specific guidance for occupational therapy, physical therapy, speech language pathology/therapy, and psychology/neuropsychology across all PD stages., Conclusions: Rehabilitative interventions should be an essential component in the comprehensive treatment of PD, from diagnosis to advanced disease. Greater education and awareness of the benefits of rehabilitative services for people with PD and their care partners, and further evidence-based and scientific study are encouraged.
- Published
- 2024
- Full Text
- View/download PDF
46. Correction to: A case of childhood‑onset dystonia‑parkinsonism due to homozygous parkin mutations and effect of globus pallidus deep brain stimulation.
- Author
-
Garrì F, Ciprietti D, Lerjefors L, Landi A, Pilleri M, Biundo R, Salviati L, Carecchio M, and Antonini A
- Published
- 2023
- Full Text
- View/download PDF
47. The pharmacological management of the behavioral aspects of Parkinson's disease: an update.
- Author
-
Campagnolo M, Emmi A, Biundo R, Fiorenzato E, Batzu L, Chaudhuri KR, and Antonini A
- Subjects
- Humans, Dopamine therapeutic use, Quality of Life, Randomized Controlled Trials as Topic, Parkinson Disease drug therapy, Parkinson Disease complications, Psychotic Disorders drug therapy, Antipsychotic Agents therapeutic use
- Abstract
Introduction: Behavioural symptoms are common manifestations of Parkinson's disease and include depression, anxiety, impulse control disorders, hallucinations, psychosis, and cognitive dysfunction. They remain inadequately addressed in many patients despite their relevance for quality of life and disability. This applies also to impulse control disorders where the most common approach in recent literature is to refrain from using dopamine agonists without consideration about their potential benefit on motor complications., Areas Covered: We conducted a narrative review searching for articles on behavioral symptoms in Parkinson disease and selected those which included involved neurotransmitters such as dopamine, noradrenaline, serotonin, acetylcholine. We specifically focused our search on open-label and randomized double-blind studies and biomarkers which could best characterize these clinical manifestations., Expert Opinion: Management of Parkinson disease behavioural manifestations lacks clear guidelines and standardized protocols beside general suggestions of dose adjustments in dopamine replacement therapy and use of antidepressants or antipsychotic drugs with little consideration of patients' age, sex, comorbidities, and motor status. We suggest a pragmatic approach which includes education of affected patients and caring people, dealing with complex cases by experienced multidisciplinary teams, use of cognitive behavioural therapy, and psychological counselling to complement drug treatment.
- Published
- 2023
- Full Text
- View/download PDF
48. A case of childhood-onset dystonia-parkinsonism due to homozygous parkin mutations and effect of globus pallidus deep brain stimulation.
- Author
-
Garrì F, Ciprietti D, Lerjefors L, Landi A, Pilleri M, Biundo R, Salviati L, Carecchio M, and Antonini A
- Subjects
- Humans, Globus Pallidus diagnostic imaging, Mutation genetics, Ubiquitin-Protein Ligases genetics, Treatment Outcome, Dystonia genetics, Dystonia therapy, Deep Brain Stimulation, Dystonic Disorders genetics, Dystonic Disorders therapy, Parkinsonian Disorders
- Published
- 2023
- Full Text
- View/download PDF
49. Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?
- Author
-
Bayram E, Batzu L, Tilley B, Gandhi R, Jagota P, Biundo R, Garon M, Prasertpan T, Lazcano-Ocampo C, Chaudhuri KR, and Weil RS
- Subjects
- Humans, Quality of Life, Cognition, Cholinesterase Inhibitors, Parkinson Disease complications, Cognitive Dysfunction therapy
- Abstract
Background: Cognitive impairment is common in Parkinson's disease (PD) and has a substantial impact on quality of life. Despite numerous trials targeting various PD features, we still lack effective treatments for cognition beyond cholinesterase inhibitors., Objective: To identify the gaps in recent clinical trials with cognitive outcomes in PD and consider areas for improvement., Methods: We examined recent clinical trials with cognitive outcomes in PD registered on ClinicalTrials.gov, excluding trials without cognitive outcomes, non-interventional studies, and in atypical Parkinsonian disorders. Included trials were categorized by treatment approach (investigational medicinal product, behavioral, physical activity, device-based). Details of trial design and outcomes were collected., Results: 178 trials at different stages of trial completion were considered. 46 trials were completed, 25 had available results. Mean follow-up duration was 29.9 weeks. Most common cognitive measure was Montreal Cognitive Assessment. Most were performed in North America or Europe. Majority of the participants identified as non-Hispanic and White. Only eight trials showed improvement in cognition, none showed improvement beyond four months. These included trials of international medicinal products, cognitive and physical interventions and devices. GRADE certainty levels ranged from Moderate to Very Low. Only mevidalen had a Moderate certainty for potential clinical effectiveness., Conclusions: Amongst a large number of trials for cognition in PD, only a small proportion were completed. Few showed significant improvement, with no proven long-lasting effects. Trial design, lack of enrichment for at-risk groups, short follow-up duration, insensitive outcome measures likely contribute to lack of detectable benefit and should be considered in future trials., Competing Interests: Declaration of competing interest KRC is supported by the Wellcome Trust and is in the advisory board of Roche and Scion; RSW is supported by the Wellcome Trust (205167/Z/16/Z)., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
50. Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
- Author
-
Emmi A, Sandre M, Russo FP, Tombesi G, Garrì F, Campagnolo M, Carecchio M, Biundo R, Spolverato G, Macchi V, Savarino E, Farinati F, Parchi P, Porzionato A, Bubacco L, De Caro R, Kovacs GG, and Antonini A
- Subjects
- Humans, alpha-Synuclein metabolism, Glial Fibrillary Acidic Protein metabolism, Gliosis, Duodenum chemistry, Duodenum metabolism, Duodenum pathology, Parkinson Disease pathology
- Abstract
Background: The role of the gut-brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α-synuclein (αSyn). However, the extent and the characteristics of pathology in the enteric nervous system have not been fully investigated., Objective: We characterized αSyn alterations and glial responses in duodenum biopsies of patients with PD by employing topography-specific sampling and conformation-specific αSyn antibodies., Methods: We examined 18 patients with advanced PD who underwent Duodopa percutaneous endoscopic gastrostomy and jejunal tube procedure, 4 untreated patients with early PD (disease duration <5 years), and 18 age- and -sex-matched healthy control subjects undergoing routine diagnostic endoscopy. A mean of four duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti-aggregated αSyn (5G4) and glial fibrillary acidic protein antibodies. Morphometrical semiquantitative analysis was performed to characterize αSyn-5G4
+ and glial fibrillary acidic protein-positive density and size., Results: Immunoreactivity for aggregated α-Syn was identified in all patients with PD (early and advanced) compared with controls. αSyn-5G4+ colocalized with neuronal marker β-III-tubulin. Evaluation of enteric glial cells demonstrated an increased size and density when compared with controls, suggesting reactive gliosis., Conclusions: We found evidence of synuclein pathology and gliosis in the duodenum of patients with PD, including early de novo cases. Future studies are required to evaluate how early in the disease process duodenal pathology occurs and its possible contribution to levodopa effect in chronic patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., (© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.)- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.